Journal
IMMUNITY
Volume 53, Issue 4, Pages 724-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2020.07.019
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases [1R01AI146101, R01AI123738]
- National Institute of Allergy and Infectious Diseases Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
- NIH [T32AI055400, R21AI129531, R21AI142638]
- Peer Reviewed Medical Research Program [PR182551]
- NIAID [AI142596, AI124429]
- State of North Carolina from the CARES Act Funds
- Cancer Research Institute
- National Heart, Lung, And Blood Institute [F30HL145907]
- BioNTech
- [NIH R01 AI129868]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL145907] Funding Source: NIH RePORTER
Ask authors/readers for more resources
SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4(+) and CD8(+) T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available